218 related articles for article (PubMed ID: 36372627)
21. Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.
Hiester A; Fingerhut A; Niegisch G; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Loy V; Wittekind C; Hartmann M; Albers P
Eur J Cancer; 2021 Sep; 155():64-72. PubMed ID: 34371444
[TBL] [Abstract][Full Text] [Related]
22. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
[TBL] [Abstract][Full Text] [Related]
23. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.
Mano R; Di Natale R; Sheinfeld J
Urol Oncol; 2019 Mar; 37(3):209-218. PubMed ID: 30446455
[TBL] [Abstract][Full Text] [Related]
24. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
25. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment.
Weissbach L; Bussar-Maatz R; Flechtner H; Pichlmeier U; Hartmann M; Keller L
Eur Urol; 2000 May; 37(5):582-94. PubMed ID: 10765098
[TBL] [Abstract][Full Text] [Related]
26. Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort.
Taylor J; Becher E; Wysock JS; Lenis AT; Litwin MS; Jipp J; Langenstroer P; Johnson S; Bjurlin MA; Tan HJ; Lane BR; Huang WC
Eur Urol Focus; 2021 Nov; 7(6):1403-1408. PubMed ID: 32682794
[TBL] [Abstract][Full Text] [Related]
27. Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II A/B Seminomas: A Systematic Review and Meta-Analysis.
Melão BVLA; de Amorim LGCR; Sanches MR; Gomes GV; Gewehr DM; Moreira LHO; da Silva TP; Lobo MM; Bechara GR
Int Braz J Urol; 2024; 50(4):415-432. PubMed ID: 38701185
[TBL] [Abstract][Full Text] [Related]
28. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update.
Bhayani SB; Ong A; Oh WK; Kantoff PW; Kavoussi LR
Urology; 2003 Aug; 62(2):324-7. PubMed ID: 12893344
[TBL] [Abstract][Full Text] [Related]
29. Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours.
Gerdtsson A; Negaard HFS; Almås B; Bergdahl AG; Cohn-Cedermark G; Glimelius I; Halvorsen D; Haugnes HS; Hedlund A; Hellström M; Holmberg G; Karlsdóttir Á; Kjellman A; Larsen SM; Thor A; Wahlqvist R; Ståhl O; Tandstad T
BJU Int; 2024 Jun; 133(6):717-724. PubMed ID: 38293778
[TBL] [Abstract][Full Text] [Related]
30. The role of primary retroperitoneal lymph node dissection in the treatment of stage II seminoma.
Sigg S; Fankhauser CD
Curr Opin Urol; 2023 Jul; 33(4):245-251. PubMed ID: 37144886
[TBL] [Abstract][Full Text] [Related]
31. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
32. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.
Pierorazio PM; Cheaib JG; Patel HD; Gupta M; Sharma R; Zhang A; Tema G; Bass EB
J Urol; 2021 Feb; 205(2):370-382. PubMed ID: 32915080
[TBL] [Abstract][Full Text] [Related]
34. Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma.
Joyce DD; Sharma V; Wymer KM; Moriarty JP; Borah BJ; Walia A; Costello BA; Pagliaro LC; Daneshmand S; Leibovich BC; Boorjian SA
J Natl Cancer Inst; 2024 Mar; 116(3):468-475. PubMed ID: 37819776
[TBL] [Abstract][Full Text] [Related]
35. Primary retroperitoneal lymph node dissection for clinical stage II seminoma: A systematic review and meta-analysis of safety and oncological effectiveness.
Kardoust Parizi M; Margulis V; Bagrodia A; Bekku K; Klemm J; Matsukawa A; Alimohammadi A; Motlagh RS; Mostafaei H; Laukhtina E; Shariat SF
Urol Oncol; 2024 Apr; 42(4):102-109. PubMed ID: 38360519
[TBL] [Abstract][Full Text] [Related]
36. Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.
Tachibana I; Alabd A; Whaley RD; McFadden J; Piroozi A; Hassoun R; Kern SQ; King J; Adra N; Rice KR; Foster RS; Einhorn LH; Cary C; Masterson TA
Urol Oncol; 2023 Sep; 41(9):394.e1-394.e6. PubMed ID: 37543446
[TBL] [Abstract][Full Text] [Related]
37. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.
Lloyd P; Hong A; Furrer MA; Lee EWY; Dev HS; Coret MH; Adshead JM; Baldwin P; Knight R; Shamash J; Alifrangis C; Stoneham S; Mazhar D; Wong H; Warren A; Tran B; Lawrentschuk N; Neal DE; Thomas BC
World J Urol; 2022 Jan; 40(1):119-126. PubMed ID: 34599350
[TBL] [Abstract][Full Text] [Related]
39. Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant?
Overs C; Beauval JB; Mourey L; Rischmann P; Soulié M; Roumiguié M; Doumerc N
World J Urol; 2018 Apr; 36(4):655-661. PubMed ID: 29353314
[TBL] [Abstract][Full Text] [Related]
40. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer.
Calaway AC; Einhorn LH; Masterson TA; Foster RS; Cary C
Eur Urol; 2019 Nov; 76(5):607-609. PubMed ID: 31174891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
